Cargando…

Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological features and treatments. Although the overall survival (OS) of patients with ALL has recently improved considerably, owing to the application of conventional chemo-therapeutic agents, approximately 20% of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Morales, Silvia, Aranda-Uribe, Ivan Sammir, Pérez-Amado, Carlos Jhovani, Ramírez-Bello, Julian, Hidalgo-Miranda, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636671/
https://www.ncbi.nlm.nih.gov/pubmed/34867958
http://dx.doi.org/10.3389/fimmu.2021.737340
_version_ 1784608575130173440
author Jiménez-Morales, Silvia
Aranda-Uribe, Ivan Sammir
Pérez-Amado, Carlos Jhovani
Ramírez-Bello, Julian
Hidalgo-Miranda, Alfredo
author_facet Jiménez-Morales, Silvia
Aranda-Uribe, Ivan Sammir
Pérez-Amado, Carlos Jhovani
Ramírez-Bello, Julian
Hidalgo-Miranda, Alfredo
author_sort Jiménez-Morales, Silvia
collection PubMed
description Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological features and treatments. Although the overall survival (OS) of patients with ALL has recently improved considerably, owing to the application of conventional chemo-therapeutic agents, approximately 20% of the pediatric cases and 40–50% of the adult patients relapse during and after the treatment period. The potential mechanisms that cause relapse involve clonal evolution, innate and acquired chemoresistance, and the ability of ALL cells to escape the immune-suppressive tumor response. Currently, immunotherapy in combination with conventional treatment is used to enhance the immune response against tumor cells, thereby significantly improving the OS in patients with ALL. Therefore, understanding the mechanisms of immune evasion by leukemia cells could be useful for developing novel therapeutic strategies.
format Online
Article
Text
id pubmed-8636671
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86366712021-12-03 Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia Jiménez-Morales, Silvia Aranda-Uribe, Ivan Sammir Pérez-Amado, Carlos Jhovani Ramírez-Bello, Julian Hidalgo-Miranda, Alfredo Front Immunol Immunology Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological features and treatments. Although the overall survival (OS) of patients with ALL has recently improved considerably, owing to the application of conventional chemo-therapeutic agents, approximately 20% of the pediatric cases and 40–50% of the adult patients relapse during and after the treatment period. The potential mechanisms that cause relapse involve clonal evolution, innate and acquired chemoresistance, and the ability of ALL cells to escape the immune-suppressive tumor response. Currently, immunotherapy in combination with conventional treatment is used to enhance the immune response against tumor cells, thereby significantly improving the OS in patients with ALL. Therefore, understanding the mechanisms of immune evasion by leukemia cells could be useful for developing novel therapeutic strategies. Frontiers Media S.A. 2021-11-18 /pmc/articles/PMC8636671/ /pubmed/34867958 http://dx.doi.org/10.3389/fimmu.2021.737340 Text en Copyright © 2021 Jiménez-Morales, Aranda-Uribe, Pérez-Amado, Ramírez-Bello and Hidalgo-Miranda https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jiménez-Morales, Silvia
Aranda-Uribe, Ivan Sammir
Pérez-Amado, Carlos Jhovani
Ramírez-Bello, Julian
Hidalgo-Miranda, Alfredo
Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
title Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
title_full Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
title_fullStr Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
title_full_unstemmed Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
title_short Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
title_sort mechanisms of immunosuppressive tumor evasion: focus on acute lymphoblastic leukemia
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636671/
https://www.ncbi.nlm.nih.gov/pubmed/34867958
http://dx.doi.org/10.3389/fimmu.2021.737340
work_keys_str_mv AT jimenezmoralessilvia mechanismsofimmunosuppressivetumorevasionfocusonacutelymphoblasticleukemia
AT arandauribeivansammir mechanismsofimmunosuppressivetumorevasionfocusonacutelymphoblasticleukemia
AT perezamadocarlosjhovani mechanismsofimmunosuppressivetumorevasionfocusonacutelymphoblasticleukemia
AT ramirezbellojulian mechanismsofimmunosuppressivetumorevasionfocusonacutelymphoblasticleukemia
AT hidalgomirandaalfredo mechanismsofimmunosuppressivetumorevasionfocusonacutelymphoblasticleukemia